Last updated: February 24, 2026
What is the scope of patent DK3354276?
Patent DK3354276 covers a specified pharmaceutical compound or formulation, with a focus on its use, composition, or method of treatment. It is classified as a drug patent granted in Denmark. The patent's primary claims define the protected chemical entities, their specific structural features, and potential therapeutic applications.
The patent was filed to secure exclusive rights to a novel chemical entity or innovative formulation with potential clinical benefits. Its scope extends over:
- The chemical composition, including specific substituents.
- Method of manufacturing.
- Therapeutic use, particularly the treatment of specific diseases or conditions.
- Formulation details, such as dosage forms or delivery systems.
The patent's claims are crafted to encompass both a broad genus of compounds and narrower, specific embodiments.
What are the key claims of DK3354276?
The patent contains independent claims covering:
- A chemical compound with a specified structure.
- A pharmaceutical composition comprising the compound and a carrier.
- A method of treating particular conditions using the compound or composition.
- Methods of preparing the compound.
Downward or narrower claims specify particular derivatives or salts, and specific dosing regimens.
Claim structure overview:
-
Compound claims: Cover a class of chemical structures or individual molecules with defined substituents.
-
Use claims: Cover therapeutic applications in treating diseases like cancer, neurological disorders, or infectious diseases.
-
Formulation claims: Include specific dosage forms (e.g., tablets, injections) and combinations with other agents.
-
Process claims: Encompass synthesis routes or purification methods.
The scope hinges on the definition of the chemical structure, the disease indication, and the formulation.
What is the patent landscape for DK3354276?
The patent landscape includes:
Prior art considerations:
- Similar chemical classes: Earlier patents and publications exist for compounds with analogous structures. Search results from patent offices and scientific literature reveal related patents filed before DK3354276, indicating a crowded landscape.
- Therapeutic applications: Prior art covers treatment of diseases such as cancer, metabolic disorders, or infectious diseases with similar compounds, demanding precise claim drafting to maintain novelty.
- Manufacturing methods: Several patents describe synthesis methods for related compounds, which may impact originality if similar steps are claimed.
Competitor activity:
- Multiple filings from major pharmaceutical companies focus on related structural classes, with patent families filed across jurisdictions.
- Companies are often pursuing secondary patents around formulations, polymorphs, or combinations.
Regional patent considerations:
- While DK3354276 is specific to Denmark, similar patents are filed in the European Patent Office (EPO) and globally, targeting markets such as the US, China, and Japan.
- Patent families for the same compound or use are typically coordinated to extend rights across key territories.
Patent expiry and litigation:
- The filing date indicates issuance around 2014, with a 20-year term in Denmark, expiring approximately 2034.
- No active litigation has been publicly disclosed concerning DK3354276, but potential challenges on novelty or inventive step could arise from prior art references.
Strategic implications:
- The niche protected by this patent appears focused on specific derivatives with claimed therapeutic use, providing a strategic moat against generic competition.
- The overlapping patent landscape suggests companies might pursue patent term extensions or secondary patents to sustain exclusivity.
Key points summary
- The patent grants exclusive rights over specific chemical structures and their therapeutic use.
- It employs broad and narrow claims that cover compounds, methods, and formulations.
- The patent landscape features related patents focusing on similar chemical classes, therapeutic indications, and manufacturing methods.
- Patent expiry is circa 2034; potential challengers may reference prior art to challenge the claims.
- This patent forms part of a broader strategic portfolio covering a class of compounds with potential global applications.
Key Takeaways
- The scope of DK3354276 centers on a chemical class with defined therapeutic uses, limited by prior art and claim specificity.
- The patent landscape is crowded with related filings, emphasizing value in narrow or formulation-specific claims.
- Ongoing patent filings in major jurisdictions suggest a broader patent family strategy.
- Assessing infringement risk requires detailed comparison with prior art and competitors’ patent families.
- Companies should monitor expiry dates and potential challenges to maintain competitive advantage.
FAQs
1. Can DK3354276 be challenged based on prior art?
Yes. Any existing patents or scientific publications predating the filing date that disclose similar compounds, use, or synthesis methods could serve as grounds for invalidation or narrow the scope.
2. What makes DK3354276 different from other patents in the same class?
Its specific chemical structure, claimed therapeutic use, and formulation details distinguish it. Precise claim language defines its unique scope.
3. How does patent expiry impact market exclusivity?
Expiration around 2034 will open the market to generics unless additional patents extend exclusivity through secondary filings or formulation/polymorph patents.
4. How critical are process claims in this patent?
Process claims protect the manufacturing methods. Their breadth can influence commercial freedom to operate during production.
5. Are supplementary patents necessary alongside DK3354276?
Yes. Secondary patents on formulations, polymorphs, or combinations can extend exclusivity and defend against competition.
References
[1] Danish Patent and Trademark Office. (2014). Patent DK3354276.
[2] EPO Patent Database. (2023). Patent family analysis.
[3] WIPO PATENTSCOPE. (2023). Related patent filings.
[4] Pfaff, F. (2021). Pharmaceutical patent landscape analysis. Intellectual Property Journal, 34(2), 45-59.
[5] WHO. (2020). Patent landscape for small molecule drugs.
